BACKGROUND Liver metastases secondary to breast cancer are associated with
unfavourable prognosis. Radioembolization with ytrrium-90 is an emerging option for …

Emerging evidence regarding the effectiveness of locoregional therapies (LRTs) for breast
cancer has prompted investigation of the potential role of interventional radiology (IR) in the …

Aim: To compare toxicity, response, and survival outcomes of patients with hepatic
metastases from breast cancer who underwent transarterial chemoembolization (TACE) or …

Cancer has become the leading cause of mortality in America, and the majority of patients
eventually develop hepatic metastasis. As liver metastases are frequently unresectable, the …

Metastatic liver disease is a major cause of cancer-related morbidity and mortality. Surgical
resection is considered the only curative treatment, yet only a minority is eligible. Patients …

Purpose To determine the relationship of tumoral and nontumoral radiation dose to
response and toxicity after transarterial radioembolization (TARE) of breast cancer liver …

While the most compelling levels of evidence for the use of Yttrium-90 (90 Y)
radioembolization are in patients with hepatocellular carcinoma and hepatic metastases …

Purpose The aim of the study was to evaluate the effects of tumour dose on tumour response
and overall survival (OS) in patients with chemo-refractory metastatic breast cancer (MBC) to …

Transarterial radioembolization (TARE) with 90 Y-loaded microspheres is an established
therapeutic option for inoperable hepatic tumors. Increasing knowledge regarding TARE …

Purpose Our purpose was to retrospectively evaluate the safety and efficacy of transarterial
hepatic radioembolization (TARE) treatment with yttrium-90 labeled glass microspheres in …